Table 1

Characteristics of the 42 eligible patients treated with IL-12

NHLHDCombined
Eligible patients321042
Evaluable for toxicity321042
Evaluable for response291039
Age (yrs)
 Median503049
 Range24–7622–6522–76
Male/female11/215/516/26
NHL32
 Diffuse large cell16
 Follicular grade I/II11
 Small lymphocytic2
 Mantle cell3
No. of prior regimens
 Median333
 Range1–41–41–4
Prior stem cell transplantation61016
Elevated pretreatment serum LDH concentration10313
Route of IL-12 administration
 Intravenous11011
 Subcutaneous211031
  • Abbreviation: LDH, lactate dehydrogenase.